{"name":"Sage Therapeutics","slug":"sage-therapeutics","ticker":"SAGE","exchange":"NASDAQ","domain":"sagerx.com","description":"Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe and rare CNS disorders. The company's lead product candidate, SAGE-324, is being investigated for the treatment of essential tremor. Sage Therapeutics has a strong pipeline of product candidates in various stages of development, including SAGE-324, which has shown promising results in clinical trials.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Barry Greene","sector":"CNS / Neuroscience","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$550M","metrics":{"revenue":45000000,"revenueGrowth":-52.3,"grossMargin":0,"rdSpend":225895000,"netIncome":-400666000,"cash":547222000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Sage Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Sage Therapeutics reported its fourth quarter and full year 2023 financial results, with net product revenue of $13.8 million for the quarter and $44.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Sage Therapeutics Announces Collaboration with the Michael J. Fox Foundation for Parkinson's Research","summary":"Sage Therapeutics announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to support the development of SAGE-324 for the treatment of essential tremor.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"Sage Therapeutics Receives FDA Fast Track Designation for SAGE-324 for the Treatment of Essential Tremor","summary":"Sage Therapeutics received FDA Fast Track designation for SAGE-324 for the treatment of essential tremor.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxQMFJUZlhhdkVXSmhlMjZOb05qUVlqNGsxemV2azMtRFRBaFNSSHBRbmlYeHEyWEtPWkxtaDNrYzJJV2V2QXBqTE5oODYzX2ZTb29XbEZEVDAyTHNMVEFFSG4xQVNVOTZXa1RxVjBmVkhZM2tSc3Vsa0EwR1FnZVFWMEg5SzlBd2hHVUZrN2NoXzk1WUZkejk2ZVVzMVlZS1hRNDB3ZGN1OEZMaGhzbG1YblFoNTFTWUZfdllINTR4OUFBU3JuNmxqTlczWlNXdVZWM3hWcHNRUm1wcXN5UzNacVlVbUtmTzBCMmt3OFpZalBTMTk4OWZ2TWc2LUFMeUQ4cEJZRVFpVC01ZVRaY3Npd0VnRmZmeEV1Uk5sc1loeXJSOVFuUGt6S3h4U0Z0LVB4a3lSNExTcXlKeUZZbmc3c2ZaU01OZU1tRFVRWTByU0xhQmpVeEtr?oc=5","date":"2026-03-31","type":"pipeline","source":"MSN","summary":"Sage Therapeutics Stock Jumps 36% on Supernus Acquisition Announcement - MSN","headline":"Sage Therapeutics Stock Jumps 36% on Supernus Acquisition Announcement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPZWhMUjJ4NEVxdmhoUXVQMm4xT0MwejFkY0RqQnZfVkEzUUtIT1Z3TjdRVThucHBZb3lUdG5rOGhqRk9NSGFuLVVacUdHS2NQVXgxVWZRNUthZnUzdXJNcWN1OC1JSzRYdEI5NWh2bS1TdFJfTTg0V0hxNHdjRHFUQzRHTTQzZw?oc=5","date":"2025-09-02","type":"pipeline","source":"Yahoo Finance","summary":"Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - Yahoo Finance","headline":"Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOQlJ5MjNpWk81aWE4Njdld3RrNGg4MzBITHFxV3FMeG84WmxfbVBXTHVSMktUQXJtbENLMWIxQ3NxTzVQeEZqaFdXTExNWTV6R1JxS1dCQzZrelRQZDRFUHlJb2ZqSHZ0bmtxTnlXSXM3eTE1ZHdIU25OTWRyZ1pEVjhwYlBxY2UzWmpxSU5nMzRuRXBjTTNxZnpXM1ZnQkZS?oc=5","date":"2025-08-01","type":"trial","source":"The Clinical Trial Vanguard","summary":"Supernus Pharma Completes Sage Therapeutics Acquisition - The Clinical Trial Vanguard","headline":"Supernus Pharma Completes Sage Therapeutics Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbnR1S0tKYjdDMmRiQ2pZdEdvR2ZvQUFLTkd1N0E1Wm1rSjJXTDNhMTNubUtzS0xSS2c5Z1FuMGpuOWJ3WTZKOWVSQWxjTEhESGM0TDZoMTdUWVIxaF9TUFJtUEl2bHhZMVk5UlNPR1lrRTdDbjhua1M0NmJFdndXTFhWMzVyUFNrZEpkSmI5R0dLTmZuZXBmRkdWOUdxOFlia2FSUFJkMFhOTU5zWmxfa2Ixa2RGZTVnQ2k2ejlGbDJobXluazBGRktUT1NudjVUQllPUkljeXMxQmc?oc=5","date":"2025-07-31","type":"pipeline","source":"GlobeNewswire","summary":"Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire","headline":"Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPYXhRVGFNc1ExeHc2dVhHOFU0eThtT0E4S0Y3ZHE1a3ZLNkFMZldwdmt3djZBcU11QlZ6Mjd0Q283Q3hZTmVxS3NQbjNSVndNbjhHX0JkWkR0V2swN0JnY2NfMTBHZHg1S3ZXTjdlMzlhRW9DbE5EdmdVYzFZN1M0QmhncldkQ2lkWHRDb0FYcGhROHBld3NQVWhET0hMaFZaRDJSYXIyeUpzZTJ6LXRqMjZhSVBHZnU3cEZuYURSYUVMbkxK?oc=5","date":"2025-07-31","type":"pipeline","source":"Investing.com","summary":"Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com","headline":"Supernus completes acquisition of Sage Therapeutics for $8.50 per share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFBCX1BFaEw4TTBBSXpGYkZ2UERoV3I3VmpXVlozbWs3LVlmQjhKM2lFaF9XVm9nRzhKZGI4U1plbFBXS1ZaUjNBSldoT05VR0tSamN5d0hZVzhuUEVfOFg4RWo0eDVLWDNTWlJKZTNucnRDeWxQcnRV?oc=5","date":"2025-06-30","type":"pipeline","source":"statnews.com","summary":"Sage Therapeutics cuts most of its workforce following acquisition - statnews.com","headline":"Sage Therapeutics cuts most of its workforce following acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOZTJhVm9QU1VoYlByaFdiSUFLZmtRYXVQR2RUMG5FOTlwV19tblpvbkdnZEhiOHl5UG8xV1I2bXlFdy1hMGx5YWxYdkFWdUh3ZFlHWnhjaVlzeTk3ZnEtYzlmZ2JYQUFNN0Z6WnVwZUVhV3ZBOFlpSkhVVzk2dmZUcXhZc05mbzNQejV5ZWhLMERmOTBuazgta2xB?oc=5","date":"2025-06-30","type":"pipeline","source":"Fierce Pharma","summary":"Sage lays off entire staff of 338 amid takeover by Supernus - Fierce Pharma","headline":"Sage lays off entire staff of 338 amid takeover by Supernus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQOVNqSlVFeFVxc0VQaVFoaG4ycXZpdVdNVmx4SVprZzZkZlNTd3VfYlFnQXZVUzREdTlWWUEySXlOT05aWHBPRklOVG4ycGZDS3JIYzJZU2RHc0NfaUdPM0E1Xzh3QkFENzhEeTBzNmZOeEc1QXd5WWIyS0JaQ0JZR2tVOE45ZGVYWVVmYkxFZTlCRFNzN2c0?oc=5","date":"2025-06-16","type":"pipeline","source":"BioPharma Dive","summary":"Sage, following setbacks, to sell to Supernus for $561M - BioPharma Dive","headline":"Sage, following setbacks, to sell to Supernus for $561M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQa2RyUW0zSl9ESlhnUFZqamtfeUV2T0tuc3k4d05zQndWTEtya3dMMWt5Qzk2NDhvX0Fidl9BZGk3QWpNdTY0aVRHM2JNTTZWdHpWdkJvU2FhaVg3LUh5Nlo4dkllMHlGRXFlb2pWQ1gwWW1KZFM2OTE1Y3RfOXBjUmQ1S2pQV3pJNmMxNWdUdkNkT1k0NG5sN3ln?oc=5","date":"2025-06-16","type":"pipeline","source":"Investor's Business Daily","summary":"Beleaguered Biotech Snapped Up In $561 Million Bid - Investor's Business Daily","headline":"Beleaguered Biotech Snapped Up In $561 Million Bid - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNamdHb2Fna0czcW5JOWhuTThPaGZEb256dmI1a24ycXY3MnN2MGoyVk5zeGVKQXZqRjZDclRCazNQeUptZThsZV9mMVVVY25vOVppRnpSa0V5b2MxNHlscFhsU0JraFNaWEE4Y3hsQkxUbmdzRG5iT0lvM2lXYTV0Y2x1TFhKeGxab0NKajAxZ0pfWi1BNnhiVGdlX01MTzlXOWNpeFpmbEhmSnNrcHRheUxFZHhEbUVEQ0NZaUNrOFo1emtHRDg4TzdVdEp4UQ?oc=5","date":"2025-06-16","type":"deal","source":"Reuters","summary":"Supernus enters depression drug market with up to $795 million Sage deal - Reuters","headline":"Supernus enters depression drug market with up to $795 million Sage deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5UUm9BempfTTFRUGdFZE1qcnFfbFlsSndHZFZzSk9qblpDZUZLMWVRdkVVQUVycThGZnRrU01lT19wQnNQUWp3Qk5UbjVheXY5dE1V?oc=5","date":"2025-06-16","type":"pipeline","source":"firstwordpharma.com","summary":"Having rebuffed Biogen, Sage settles on takeout by Supernus - firstwordpharma.com","headline":"Having rebuffed Biogen, Sage settles on takeout by Supernus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxONzhtYUs3T1RwS0hzRmo1aGlELW9LRHlZSmJzeE8zLWxZaWliU29vT2p6amlDVVhzbnctZkZDNF80ZnFsc2I5MThZejBEQ3huaWtpRUhDN285OWZ6Zi1BOF9iQU1wR1Q5c1JELTU4ejRDcWdDMG5TLTJabHB4VjNpZldkeEFsek05TkdXN1ZXbw?oc=5","date":"2025-06-16","type":"pipeline","source":"Barron's","summary":"Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's","headline":"Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Ultragenyx Pharmaceutical","Cerevel Therapeutics","Pfizer"],"therapeuticFocus":["Neurology","Psychiatry"],"financials":{"source":"sec_edgar+yahoo","revenue":41243000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":41243000,"period":"2024-12-31"},{"value":86455000,"period":"2023-12-31"},{"value":86455000,"period":"2023-12-31"},{"value":7686000,"period":"2022-12-31"},{"value":7686000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":225895000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-400666000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":547222000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}